Atea Pharmaceuticals (AVIR) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Ovid Therapeutics (OVID) over the past year, gaining 66.3% versus a gain of 48.1%. Over five years, OVID leads with a -35.0% price change compared with -86.9% for AVIR. Ovid Therapeutics is the larger company by market cap ($457.0 million vs $413.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | OVID |
|---|---|---|
| Share price | $5.16 | $2.34 |
| Market cap | $413.46M | $457.00M |
| 1-day change | +2.89% | -0.85% |
| YTD return | +44.40% | +43.56% |
| 1-year return | +66.29% | +48.10% |
| 5-year return | -86.88% | -35.00% |
| EPS (TTM) | $-2.09 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $3.11 |
| 52-week low | $2.87 | $1.18 |
| Distance from 52-week high | -20.08% | -24.64% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +82.74% | +157.26% |
| Average volume | 298.98K | 1.57M |
| Shares outstanding | 80.20M | 195.30M |
| Employees | 55 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed OVID by 18.2 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
AVIR vs OVID FAQ
Which is bigger, Atea Pharmaceuticals or Ovid Therapeutics?
Ovid Therapeutics (OVID) is larger, with a market capitalization of $457.00M compared with $413.46M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, AVIR or OVID?
AVIR returned +66.29% over the past 12 months, compared with +48.10% for OVID (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.